PIR7B Antibody

What is PIR-B and what are its primary functions in the immune system?

PIR-B (Paired Immunoglobulin-like Receptor B) is an inhibitory receptor expressed predominantly on murine B cells and myeloid cells. It plays crucial roles in regulating both humoral and cellular immune responses through its constitutive binding to MHC class I molecules. PIR-B functions primarily as a negative regulator that maintains peripheral tolerance and prevents excessive immune activation.

The receptor works by constitutively binding to MHC class I molecules either on the same cells (in cis) or on different cells (in trans). This interaction triggers inhibitory signaling cascades that counterbalance activating signals. PIR-B expression increases with cellular differentiation and activation, with highest levels observed on marginal zone B cells, followed by B-1 cells and then B-2 cells .

How does PIR-B differ from PIR-A, and why is this distinction important in research?

PIR-B and PIR-A represent a pair of receptors with opposing functions. While PIR-B contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic region that mediate inhibitory signals, PIR-A associates with the FcRγ subunit to deliver activating signals. In most immune cells, PIR-B expression predominates over PIR-A, creating a baseline inhibitory tone that prevents inappropriate immune activation .

This distinction is critical in research because the balance between these receptors determines cellular responsiveness. When designing experiments, researchers must use antibodies that can specifically distinguish between PIR-A and PIR-B to accurately interpret results. The preferential expression of PIR-B on cell surfaces compared to PIR-A (as determined by flow cytometry with specific monoclonal antibodies like 6C1) suggests evolutionary pressure to maintain inhibitory regulation in the immune system .

What is the difference between immune regulatory PIR-B and PirB toxin?

Despite the similar nomenclature, these proteins are entirely different molecules with distinct functions. Immune regulatory PIR-B is a mammalian inhibitory receptor expressed on B cells and myeloid cells that recognizes MHC class I molecules and regulates immune responses. In contrast, PirB toxin (Photorhabdus insect-related toxin B) is a virulence factor produced by certain Vibrio species that causes acute hepatopancreatic necrosis disease (AHPND) in shrimp .

The distinction is crucial for researchers, as experimental approaches differ significantly when studying these proteins. PIR-B research typically focuses on immunological mechanisms, while PirB toxin research centers on pathogenicity factors in marine diseases. The antibodies developed against each would have entirely different applications in research settings .

What are the key considerations when selecting antibodies for PIR-B detection?

When selecting antibodies for PIR-B detection, researchers should consider several critical factors:

• Specificity: Choose antibodies that can distinguish between PIR-B and the closely related PIR-A. Monoclonal antibodies like 6C1 recognize shared epitopes, while others may be specific to PIR-B alone.

• Application compatibility: Verify that the antibody performs well in your intended application (flow cytometry, immunoprecipitation, Western blotting, etc.).

• Cross-reactivity: Consider whether the antibody cross-reacts with human orthologs like LILRB1 and LILRB2 if comparative studies are planned.

• Clone validation: Look for antibodies validated in knockout models (Pirb−/−) to ensure specificity.

• Epitope location: Select antibodies targeting extracellular domains for flow cytometry or functional blocking studies, versus those recognizing intracellular domains for signaling studies .

How can researchers develop monoclonal antibodies against PIR-B?

Development of monoclonal antibodies against PIR-B typically follows this methodological approach:

• Antigen preparation: Clone the PIR-B gene into an expression vector (such as pET-30a+) with appropriate restriction sites (like EcoRI and XhoI). Express the recombinant protein in a bacterial system such as E. coli BL21 with IPTG induction.

• Protein purification: Purify the recombinant protein using affinity chromatography, typically via a His-tag purification system.

• Immunization protocol: Immunize SPF-grade female BALB/c mice with purified recombinant PIR-B protein (approximately 60 μg per mouse for primary immunization), followed by multiple booster immunizations at 14-day intervals with reduced antigen amounts (approximately 30 μg).

• Antibody titer assessment: Evaluate serum antibody titers using ELISA, starting with dilutions from 1:200.

• Hybridoma generation: Fuse B cells from immunized mice with myeloma cells to create hybridomas.

• Screening and selection: Screen hybridoma supernatants for specific binding to PIR-B and absence of cross-reactivity to related proteins.

• Subcloning: Perform limiting dilution to ensure monoclonality of the antibody-producing cells .

What controls should be included when validating PIR-B antibodies?

Proper validation of PIR-B antibodies requires these essential controls:

• Genetic controls: Include samples from Pirb−/− mice as negative controls to confirm antibody specificity.

• Blocking controls: Pre-incubate antibodies with recombinant PIR-B protein to demonstrate specific blocking of detection.

• Isotype controls: Include matched isotype controls to account for non-specific binding.

• Cross-reactivity assessment: Test antibodies against cells expressing only PIR-A to evaluate potential cross-reactivity.

• Expression pattern verification: Confirm that detected expression patterns match known PIR-B distribution (highest on marginal zone B cells, higher on B-1 than B-2 cells).

• Signal inhibition: Verify that antibody binding inhibits known PIR-B functions, such as suppression of BCR-induced proliferation in B cells .

How does PIR-B contribute to autoimmune disease mechanisms?

PIR-B plays a crucial role in preventing autoimmunity through several mechanisms:

• Regulation of B-1 cell activation: PIR-B suppresses TLR9-mediated production of naturally autoreactive antibodies by B-1 cells by inhibiting Bruton's tyrosine kinase activation. In Pirb−/− mice, excessive TLR9 signaling leads to increased production of autoantibodies.

• Combined deficiency effects: While PIR-B single deficiency does not cause overt autoimmune diseases, when combined with other mutations like Fas lpr, it results in augmented production of autoantibodies such as IgG rheumatoid factor and anti-DNA IgG. This leads to glomerulonephritis, demonstrating PIR-B's role in maintaining immune tolerance.

• Control of myeloid cell activation: PIR-B regulates myeloid cells that can otherwise contribute to tissue damage in autoimmune conditions. Pirb−/− macrophages and dendritic cells show enhanced cytokine and chemokine signaling that can exacerbate inflammatory responses.

• Intestinal inflammation control: PIR-B has an inhibitory role in macrophage activation during intestinal inflammatory responses, such as in experimental colitis models .

What is the significance of PIR-B in cis versus trans interactions with MHC class I?

The cis/trans binding dynamics of PIR-B with MHC class I molecules represent a sophisticated regulatory mechanism:

• Dual recognition capability: PIR-B can recognize MHC class I molecules on the same cell surface (cis) or on different cells (trans). This versatility allows context-dependent immune regulation.

• Competition with CD8: PIR-B competes with CD8αα for binding to MHC class I molecules. Surface plasmon resonance analysis has confirmed this competitive binding. This mechanism regulates CTL activation, as PIR-B on dendritic cells blocks CD8 access to MHC class I, thereby controlling T cell responses.

• Immunological synapse regulation: During DC-CD8+ T cell interactions, the balance between cis and trans interactions determines the outcome of antigen presentation. Pirb−/− DCs provoke cytotoxic T lymphocytes more efficiently, leading to accelerated rejection of skin grafts and tumors.

• Threshold setting: Similar to Ly49A in NK cells, the cis association of PIR-B with MHC class I may restrict the number of PIR-B receptors available for trans binding, establishing activation thresholds for immune responses .

How has the role of PIR-B been expanded beyond the immune system?

Recent research has revealed unexpected functions of PIR-B beyond traditional immune regulation:

• Neuronal expression: PIR-B and its human ortholog LILRB2 are expressed on neuronal cells, suggesting roles outside the hematopoietic system.

• Novel ligand recognition: In the central nervous system, PIR-B recognizes three neuronal ligands: Neurite outgrowth inhibitor protein (Nogo)A, myelin-associated glycoprotein (MAG/Siglec-4), and oligodendrocyte myelin glycoprotein (OMgp).

• Neuronal regeneration: PIR-B functions as a determinant of neuronal regeneration by responding to these multiple ligands in the central nervous system, potentially inhibiting neural repair after injury.

• Bacterial recognition: PIR-B acts as a cell surface receptor for bacterial pathogens including Staphylococcus aureus and Escherichia coli, functioning as a pattern recognition receptor alongside TLRs and other innate immune receptors .

What techniques are most effective for analyzing PIR-B expression patterns?

Several complementary techniques provide comprehensive analysis of PIR-B expression:

• Flow cytometry: The most widely used method for detecting cell surface PIR-B, using monoclonal antibodies like 6C1. This technique allows quantification of expression levels across different cell populations and can be combined with other markers to identify specific subsets.

• Western blotting: Useful for analyzing total PIR-B protein levels and assessing post-translational modifications. This approach distinguishes PIR-B from PIR-A based on molecular weight differences.

• Quantitative RT-PCR: Measures PIR-B transcript levels, allowing assessment of expression regulation at the transcriptional level.

• Immunohistochemistry/immunofluorescence: Enables visualization of PIR-B distribution in tissues and determination of its subcellular localization.

• Reporter systems: Using PIR-B promoter-driven reporter constructs to track expression patterns in vivo .

How can researchers investigate PIR-B signaling mechanisms?

Investigation of PIR-B signaling requires multiple approaches:

• Phosphorylation analysis: Assess tyrosine phosphorylation of PIR-B's ITIMs following receptor engagement using phospho-specific antibodies in Western blotting or immunoprecipitation.

• Signaling intermediate recruitment: Examine recruitment of phosphatases SHP-1 and SHP-2 to phosphorylated PIR-B using co-immunoprecipitation techniques.

• Downstream signaling inhibition: Measure suppression of activating pathways, such as reduced phosphorylation of Bruton's tyrosine kinase in B cells or inhibition of MAPK pathways in myeloid cells.

• Genetic approaches: Use cells from mice with mutations in specific signaling components to dissect the PIR-B pathway.

• Proximity ligation assays: Visualize molecular interactions between PIR-B and potential signaling partners directly in cells .

What experimental systems best model PIR-B function in disease contexts?

Several experimental systems effectively model PIR-B functions in disease:

• Pirb−/− mice: The primary model system for PIR-B research, allowing investigation of its role in various immune responses. These mice show enhanced B cell activation, exaggerated mast cell responses, and heightened sensitivity to bacterial infections.

• Compound mutant models: Combining PIR-B deficiency with other mutations (e.g., Fas lpr) creates models of autoimmune disease that reveal PIR-B's role in preventing autoimmunity.

• Cell-specific conditional knockouts: Allow investigation of PIR-B function in specific cell types without systemic effects of global deletion.

• Ectopic expression systems: Forced expression of PIR-B in cells that normally lack it (e.g., T cells) provides insights into its inhibitory capabilities and ligand recognition properties.

• Infectious disease models: Challenging Pirb−/− mice with various pathogens reveals its role in antimicrobial immunity, as demonstrated with Salmonella and other bacterial infections .

How do researchers differentiate between PIR-B and its human orthologs in comparative studies?

Conducting comparative studies between murine PIR-B and human orthologs presents several challenges that can be addressed methodologically:

• Sequence and structure analysis: Perform computational alignment of murine PIR-B with human LILRB1 and LILRB2 to identify conserved regions and functional domains. Although there are differences, these receptors share similar binding to MHC class I α3 domains and β2-microglobulin.

• Functional comparison: Examine inhibitory functions in parallel assays using species-specific cell systems. Both PIR-B and LILRB molecules inhibit immune activation, but may utilize slightly different downstream signaling components.

• Cross-reactive antibodies: Identify antibodies that recognize conserved epitopes between murine and human receptors, or develop specific antibodies for each ortholog.

• Transgenic models: Generate humanized mice expressing LILRB molecules in place of PIR-B to directly compare functions in vivo .

What are the main technical challenges when working with PIR-B antibodies?

Researchers face several technical challenges when working with PIR-B antibodies:

• Specificity issues: Many antibodies cross-react with PIR-A due to high sequence homology, necessitating careful validation using Pirb−/− controls.

• Functional blocking: Developing antibodies that effectively block PIR-B function without triggering signaling requires extensive screening.

• Conformational epitopes: Some important epitopes may be conformationally dependent and lost during certain applications (e.g., Western blotting under reducing conditions).

• Variable glycosylation: PIR-B is heavily glycosylated, which can affect antibody binding and create variable results depending on cell type and activation state.

• Cis interactions: The constitutive association of PIR-B with MHC class I in cis may mask epitopes and reduce antibody accessibility in certain experimental settings .

How can researchers assess PIR-B's contribution in complex disease models?

Dissecting PIR-B's specific contributions in complex disease models requires sophisticated approaches:

• Temporal-specific deletion: Use inducible Cre-lox systems to delete PIR-B at different disease stages to determine when its function is most critical.

• Cell-specific approaches: Employ cell-specific PIR-B deletion or blocking antibodies delivered to specific tissues to isolate its function in different cellular compartments.

• Signaling pathway analysis: Use phospho-flow cytometry or mass cytometry to simultaneously assess multiple signaling pathways influenced by PIR-B in disease states.

• Transcriptomic profiling: Compare gene expression changes in wild-type versus Pirb−/− cells during disease progression to identify PIR-B-dependent pathways.

• Adoptive transfer experiments: Transfer Pirb−/− cells into wild-type hosts (or vice versa) to distinguish cell-intrinsic from environmental effects of PIR-B deficiency .